Investors

Press Releases

 
Press Releases
  Date Title View
Aug 1, 2016
WATERTOWN, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the initiation of patient dosing in a phase 1 clinical trial for intravenous (IV) TP-6076, a novel antibiotic candidate being developed for the treatment of serious and life-threatening bacterial infections, including those caused by...
Jun 28, 2016
WATERTOWN, Mass., June 28, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that it was added to the Russell Microcap® Index when the Russell Investment Group reconsti...
Jun 20, 2016
WATERTOWN, Mass., June 20, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, presented results from IGNITE1 and IGNITE2, its phase 3 eravacycline clinical trials, at the American Society of...
Jun 15, 2016
WATERTOWN, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the JMP Securities Life Sciences C...
May 23, 2016
WATERTOWN, Mass., May 23, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced seventeen data presentations at the American Society of Microbiology (ASM) Microbe 2016 Conference, taking place June 16-20 in Boston, MA.  Presentations will include information about the company's lead drug candidate, eravacycline, ...
May 12, 2016
- Additional phase 3 clinical trial in cIAI planned to support NDA filing - -Phase 3 clinical trial in cUTI planned for future supplemental NDA - - Company to host conference call at 4:30 p.m. ET today - WATERTOWN, Mass., May 12, 2016 (GLOBE NEWSWIRE) --  Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical co...
May 4, 2016
WATERTOWN, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the first quarter ended March 31, 2016. "We have remained in dialogue w...
Apr 7, 2016
WATERTOWN, Mass., April 07, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced five data presentations at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place April 9-12 in Amsterdam, Netherlands.  Presentations will include information about the company's lead dru...
Apr 6, 2016
WATERTOWN, Mass., April 06, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 15th Annual Needham & Co. Hea...
Mar 10, 2016
WATERTOWN, Mass., March 10, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 28th Annual Roth Conference o...
FirstPrevious
3
...
NextLast
= add release to Briefcase